Listen to this page using ReadSpeaker
Posts tagged age-related macular degeneration

Nobel-Prize-Winning Stem-Cell Researcher Delivers Keynote at FFB-Funded Conference in Kyoto

Shinya Yamanaka, M.D., Ph.D.It was only 10 years ago that Shinya Yamanaka, M.D., Ph.D., discovered how to convert a person’s skin cells into stem cells by tweaking just four genes. The historical breakthrough landed Dr. Yamanaka the 2012 Nobel Prize in Physiology-Medicine, because it meant that patients could be their own stem-cell donors. Known as induced pluripotent stem cells (iPSC), they are now being used to develop powerful therapies and drug-screening tools including those for the retina.

To the delight of nearly 300 retinal researchers from around the world attending the FFB-funded RD2016 meeting, September 19-24 in Kyoto, Japan, Dr. Yamanka discussed his early clinical trial for iPSC-derived retinal pigment epithelial (RPE) cells for a 78-year-old woman with advanced wet age-related macular degeneration (AMD). The study met its main goal – safety – and he and his collaborator, Masayo Takahashi, M.D., Ph.D., are planning to treat additional patients in the near future.

Continue Reading…

Pixium Vision Reports Progress in Development of Two Advanced Bionic Retina Systems

Man wearing Pixium Bionic Retina GlassesWhile several companies and laboratories around the world are at various stages of bionic-retina development, Pixium Vision  located in France, is progressing impressively down two paths for these high-tech, vision-restoring systems. Both approaches show strong, near-term potential for providing meaningful vision to people who are otherwise blind from retinal diseases such as retinitis pigmentosa and age-related macular degeneration (AMD).

Pixium recently announced that its IRIS®II bionic vision system received a CE Mark, the regulatory approval necessary for marketing medical devices and other products in Europe. The IRIS II is further down the company’s clinical development pipeline than its more technologically advanced PRIMA system, which was originally conceptualized by researchers at Stanford University, and is expected to enter a clinical trial later this year for AMD.

Continue Reading…

Back in Baltimore – VISIONS 2016, FFB’s National Conference, Returns to Its Founding City

Baltimore's Inner HarborFor the second year in a row, the Foundation Fighting Blindness’ national conference — this year titled VISIONS 2016 — will take place in FFB’s founding city of Baltimore, Maryland, June 30-July 3. More than 500 people are expected to attend the event, which will offer dozens of research- and lifestyle-focused sessions designed for people who are visually impaired and sighted as well.
Continue Reading…

A Steady Hand in Saving Vision

Dr. Robert MacLaren performing eye surgery.A retinal researcher can develop the best vision-saving stem-cell or gene therapy ever imagined, but if the doctor or surgeon can’t deliver it to the retina safely and effectively, the treatment is worthless. It could even be harmful.
Continue Reading…

Past Sun Exposure Increases AMD Risk

FFB staff members taking preventive measuresIf you’re a young or middle-aged adult who enjoys being outside in the bright sunshine, you’re probably not thinking about the risk for going blind from age-related macular degeneration (AMD). But according to a new study published in the journal Retina, you should be.
Continue Reading…

Donated Eyes Help Researchers Better Understand Retinal Diseases

a retina affected by RPMany people with retinal conditions such as retinitis pigmentosa (RP) and age-related macular degeneration don’t think they can donate their eyes after they’ve passed away. They can’t imagine anyone would want eyes that didn’t work well. But in reality, affected eyes are in big demand.
Continue Reading…

First AMD Patient Receives Argus II Bionic Retina

Ray Flynn wearing the Argus IIThere’s nothing more exciting than news about vision restoration for someone blind from a retinal disease. But a report coming from across the pond is especially compelling, because it’s about the first person with age-related macular degeneration (AMD) to receive the Argus II bionic retina.
Continue Reading…

ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research

future of retinal researchThe National Eye Institute’s (NEI) establishment of its Audacious Goals in 2013 was a watershed moment in the drive to cure blinding retinal diseases. The mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases. Most important, it means that the NEI is making significant investments in research that will benefit people with retinal conditions, such as retinitis pigmentosa, Usher syndrome, Stargardt disease, and age-related macular degeneration.
Continue Reading…

ARVO 2015 Highlight: AMD Gene Therapy Performs Encouragingly in Human Study

an AMD eyeWhile treatments such as Lucentis®, Avastin®, and Eylea® have been saving and restoring vision for people with wet age-related macular degeneration (AMD) over the last several years, they have a significant drawback: The therapies require regular injections into the eye—in some cases, monthly—for the life of the patient.
Continue Reading…

What Everyone with a Retinal Disease Should Know about Vitamin A

blue eyeIf you think of your retinas as the engines that power your vision, then vitamin A is their fuel. Without vitamin A in our diets, we wouldn’t see.
Continue Reading…